Klotho Neurosciences (NASDAQ: KLTO) Confirms NASDAQ Compliance, Advancing Neurodegenerative Disease Therapies

Klotho Neurosciences Validates Compliance with NASDAQ Requirements, Reinforcing Commitment to Neurodegenerative Disease Therapies

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a pioneering company focused on gene and cell therapies for neurodegenerative and aging-related diseases, confirms its compliance with NASDAQ listing requirements. This announcement, made on July 16, 2025, indicates that Klotho meets the minimum bid price of $1.00 and the stockholder equity threshold of $2.5 million. By meeting these standards, Klotho ensures its continued listing and trading on the NASDAQ Stock Market. The company's proactive measures to maintain compliance highlight its commitment to operational stability and investor confidence.

The compliance confirmation allows Klotho to focus on its core mission: developing innovative, disease-modifying therapies derived from the patented "anti-aging" human Klotho gene (s-KL). The company targets major neurodegenerative conditions, including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. Klotho’s approach combines proprietary cell and gene therapy programs utilizing cutting-edge DNA and RNA therapeutics with genomics-based diagnostic assays. This unique blend of technologies places Klotho at the forefront of biogenetic innovation, aiming to transform how these debilitating diseases are treated.

Klotho is supported by a seasoned management team with extensive experience in biopharmaceutical development and commercialization. This expertise positions the company for future advancements in addressing age-related disorders. With ongoing monitoring for compliance over the next year, Klotho is dedicated to upholding the stringent requirements of NASDAQ while continually pushing the boundaries of therapeutic development. The company’s ongoing efforts not only bolster its standing in the market but also underscore its commitment to improving health outcomes for aging populations facing challenging neurological conditions.

In addition to its recent compliance announcement, Klotho Neurosciences emphasizes its ongoing research and development initiatives. The company's innovative approach to gene therapy could revolutionize treatment paradigms for neurodegenerative diseases, offering hope to patients and families affected by these conditions. As Klotho continues to advance its therapeutic programs, it remains committed to leveraging its scientific expertise to foster breakthroughs in biogenetic medicine.

For more information on Klotho's research and initiatives, interested parties are encouraged to visit the company’s website at www.klothoneuro.com, where updates on its progress and developments in the neurodegenerative disease space are regularly shared.